Bold claim: Weight loss wins trump the side effects for Ozempic users, even when those side effects don’t go away. And this is the part many people miss. A recent Journal of Medical Internet Research study dives into real-world experiences of off-label Ozempic use for weight loss, revealing what drives people to keep or drop the treatment despite adverse effects.
Growing obesity and treatment options
Obesity is a chronic metabolic condition defined by excessive body fat that raises the risk of heart disease, type 2 diabetes, and cancer. Since 1990, global obesity rates have more than doubled, fueling a rise in weight-related health problems.
While lifestyle changes—like diet tweaks and regular exercise—remain the frontline approach to weight management, they often fall short for many individuals. Bariatric surgery can be effective but carries considerable risks. In contrast, GLP-1 receptor agonists (notably semaglutide) have emerged as a powerful obesity treatment, offering substantial weight loss and meaningful improvements in related health outcomes.
Semaglutide works as a GLP-1 receptor agonist that helps regulate blood glucose through multiple pathways: it suppresses glucagon, enhances insulin secretion, slows gastric emptying, and alters brain circuits that govern appetite and fullness. The first FDA-approved semaglutide formulation was marketed as Ozempic. Clinical trials show meaningful weight reductions (roughly 7.9% to 17.3%), lower HbA1c, smaller waist measurements, and better blood pressure readings. Wegovy, another semaglutide formulation, is specifically approved for obesity, though social chatter often promotes Ozempic off-label for cosmetic weight loss.
Despite strong efficacy, side effects are common. Trials report gastrointestinal issues (nausea, vomiting, constipation, diarrhea) in roughly 42% to 83% of patients, plus headaches, gallbladder problems, dehydration, anemia, and dizziness. This creates a real trade-off: people want the weight loss, but tolerating side effects remains a challenge that can influence whether they stay on treatment.
Study design and data source
Researchers used a mixed-methods infoveillance approach, combining numbers with qualitative insight, to explore how people feel about off-label Ozempic use. They conducted a thematic analysis of patient reviews on Drugs.com and then used quantitative methods to link themes with perceived efficacy and decisions to discontinue.
Drugs.com hosts reviews from more than 24,000 drugs and allows users to share narrative experiences and rate effectiveness on a 1–10 scale. Reviews discuss benefits, adverse effects, and dosing, but often lack demographic or clinical details. Data were collected in June 2023, with reviews from February to June 2023; no retrospective time limit was applied. Of 78 reviews, 60 reached thematic saturation and were analyzed in two phases: first, inductive coding of themes from the narratives, then statistical testing of how those themes related to satisfaction and discontinuation.
Key finding: efficacy drives persistence, not tolerability
Three main themes emerged from the 60 reviews. Theme 1: weight-related outcomes. Two-thirds (40 of 60) reported reductions in weight, appetite, or cravings. Specifically, 33 of 60 (55%) described weight loss at some point during treatment. Weight loss stood out as the most common positive outcome, with a median satisfaction rating of 8.5. About 37% reported appetite suppression, and 13% noticed fewer cravings for sugary or fatty foods.
However, 18% saw little weight loss or weight rebound, mirroring extended-trial data that weight loss often plateaus after roughly a year on semaglutide.
Theme 2: side effects. Around 80% reported non-weight-related symptoms, including gastrointestinal issues (62%) like nausea, vomiting, and constipation, and other bodily symptoms (67%), such as headaches, gallbladder problems, dehydration, anemia, and dizziness. While GI symptoms were common, they didn’t strongly sway overall satisfaction or the decision to continue. A few users also reported worsened depressive symptoms. Only 13% described no distressing side effects.
Theme 3: continuation decisions. Among 20 respondents, 6 planned to continue despite side effects (median satisfaction 9.0), while 14 planned to discontinue (median satisfaction 3.0). Those with higher ratings were more likely to report weight loss and appetite suppression; those with lower ratings tended to have minimal weight loss and other adverse experiences. Stomach-related side effects occurred in both groups. Everyone who planned to continue reported weight-related benefits, and adverse events occurred at similar rates in both groups.
Across 54 respondents who gave numeric ratings, opinions split cleanly: about half rated Ozempic at 1 or 10, showing polarized experiences. The statistical analysis confirmed that the 60-review subset did not differ significantly from the full 78-review dataset available at the time.
Tolerability vs. results: what truly matters
The study highlights a clear pattern: people decide to keep or ditch Ozempic mainly based on perceived weight-loss effectiveness, not just how tolerable the side effects are. While many users reported favorable weight-related outcomes—weight loss, appetite reduction, and fewer cravings—a notable minority experienced little benefit or weight regain over time.
Limitations include the self-selected, anonymous nature of online reviews, lack of demographic, dosing, or duration data, and the inability to independently verify clinical outcomes or adverse events. Still, these insights stress the importance of setting realistic expectations with patients about the benefits and limits of GLP-1R agonists for weight management. They also demonstrate how online health platforms can provide patient-centered insights that may complement traditional clinical trials.
Source: Armanious, A. et al. (2026). Patient Perceptions of Ozempic (Semaglutide) for Weight Loss: Mixed Methods Analysis of Online Medication Reviews. Journal of Medical Internet Research. 28:e78391. DOI: 10.2196/78391. https://www.jmir.org/2026/1/e78391
